9,600 Mirum Pharmaceuticals, Inc. $MIRM Shares Sold by Toth Financial Advisory Corp

Toth Financial Advisory Corp reduced its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 93.3% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 685 shares of the company’s stock after selling 9,600 shares during the period. Toth Financial Advisory Corp’s holdings in Mirum Pharmaceuticals were worth $59,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in MIRM. Juncture Wealth Strategies LLC raised its position in shares of Mirum Pharmaceuticals by 10.7% during the 3rd quarter. Juncture Wealth Strategies LLC now owns 5,330 shares of the company’s stock valued at $456,000 after buying an additional 515 shares in the last quarter. Engineers Gate Manager LP grew its position in Mirum Pharmaceuticals by 218.2% in the second quarter. Engineers Gate Manager LP now owns 8,143 shares of the company’s stock worth $953,000 after acquiring an additional 5,584 shares in the last quarter. Insight Wealth Partners LLC bought a new stake in Mirum Pharmaceuticals during the second quarter worth approximately $395,000. Integrated Wealth Concepts LLC purchased a new stake in Mirum Pharmaceuticals during the second quarter valued at approximately $27,000. Finally, Arizona State Retirement System raised its position in Mirum Pharmaceuticals by 12.6% during the second quarter. Arizona State Retirement System now owns 11,655 shares of the company’s stock valued at $1,364,000 after purchasing an additional 1,306 shares during the period.

Mirum Pharmaceuticals Trading Up 5.7%

Shares of NASDAQ MIRM opened at $86.01 on Friday. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86. The business’s 50 day moving average price is $95.08 and its 200-day moving average price is $100.89. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $63.23 and a fifty-two week high of $130.00. The company has a market cap of $5.58 billion, a price-to-earnings ratio of -5.91 and a beta of 0.61.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The business had revenue of $176.24 million for the quarter, compared to analysts’ expectations of $166.33 million. Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 36.28%. Mirum Pharmaceuticals’s revenue was up 37.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.12) EPS. On average, sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -1.31 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. TD Cowen dropped their target price on Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Wall Street Zen downgraded Mirum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, September 6th. Weiss Ratings raised shares of Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research note on Thursday, August 6th. Robert W. Baird lifted their price objective on shares of Mirum Pharmaceuticals from $123.00 to $130.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 29th. Finally, JPMorgan Chase & Co. increased their target price on shares of Mirum Pharmaceuticals from $115.00 to $125.00 and gave the company an “overweight” rating in a research note on Thursday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $143.81.

Insider Activity

In related news, CEO Christopher Peetz sold 30,000 shares of Mirum Pharmaceuticals stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $98.68, for a total transaction of $2,960,400.00. Following the completion of the sale, the chief executive officer owned 194,440 shares in the company, valued at $19,187,339.20. This trade represents a 13.37% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 658 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $100.00, for a total transaction of $65,800.00. Following the completion of the sale, the senior vice president directly owned 616 shares of the company’s stock, valued at approximately $61,600. This trade represents a 51.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 98,499 shares of company stock valued at $9,797,834. 8.32% of the stock is currently owned by company insiders.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for rare diseases of the liver and gastrointestinal system. The company’s work centers on conditions involving impaired bile acid transport and cholestasis, which can cause serious liver damage and debilitating symptoms such as itching.

Mirum’s primary commercial product is Livmarli (maralixibat), an oral ileal bile acid transporter inhibitor. In the United States, Livmarli is approved to treat cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis in eligible pediatric patients.